
Global Health Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company expects continued robust volume-driven growth, supported by increased bed capacity and expanded clinical capabilities, especially in developing hospitals like Lucknow and Patna.
- Expansion includes capacity addition: 280 beds added in H1 FY25 (150 in Lucknow, 84 in Patna, 50 in Gurugram), with focus on ramping up occupancy.
- Introduction of advanced technology, e.g., Da Vinci Xi Surgical Robot, aims to improve patient outcomes and attract more patients.
- Matured hospitals show steady revenue growth: 13.5% YoY in Q2 FY25; developing hospitals growing at 4.2% YoY.
- International patient revenue is currently around 6%, expected to grow as new NCR facilities come online, though subject to geopolitical risks.
- Focus remains on sustainable, ethical growth by strengthening existing services and expanding reach into new areas.
- Pipeline projects including new facilities in Pitampura, Mumbai, and Noida expected to contribute incrementally over 3-4 years.
See what Global Health management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No explicit mention of current or future fundraising through debt or equity in the transcript.
- The focus is on ongoing and planned capex for various projects (New facilities in Pitampura, Mumbai, Medical School, Guest House) to be funded over the next three to four years.
- Mention of capital inflow in the healthcare industry post-COVID and increased interest from the financial community in building hospitals, but no direct statement about Medanta raising funds.
- The company emphasizes sustainable and ethical growth with a long-term view, not radical or short-term capital raising.
- CFO Yogesh Kumar Gupta mentions capex plans but does not detail any planned fundraising.
- Overall, the discussion centers more around strategic investments and capex management rather than immediate fundraising plans.
See what Global Health management said on order book — free account, 30 seconds.
Capex plans
Yes- INR 300 crores budgeted for medical school build-out (4-5 lakh sq ft) on 25 acres hospital campus; timeline 3-4 years.
- Ongoing Pitampura project (Delhi) with DLF partnership; delayed due to pollution clearances but fully on track.
- Indore project currently delayed and stuck in litigation; exploring alternative expansion options.
- South Delhi project delayed due to compliance and approval issues.
- Mumbai land acquisition completed; part of INR 370 crores capex in H1 FY25.
- Total capex guidance: ~INR 470 crores on existing units and INR 500 crores for Noida project over next 3-4 years.
- Major medical equipment purchases aligned with hospital development phases.
- Focus on expanding capacity (e.g., 118 beds added in Q2 FY25 at Lucknow and Patna).
- Commitment to sustainable, ethical growth and strengthening existing facilities alongside new expansions.
Track Global Health — get its next earnings analysis in your feed
How does Global Health rank vs peers in Healthcare Services?
Pro featureHow does Global Health rank in Healthcare Services?
Compare Global Health against every Healthcare Services company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Global Health's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.